Skip to main content

Dermatology

choices2.jpg

IL-17 Switching Works in Psoriatic Disease

Oct 03, 2022

Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
Open label, multicenter study of 70 Psoriasis pts treated w/ apremilast shows no change in aortic vascular inflammation (FDG-PET) at wks 16 & 52, but did decr. several cardiometabolic biomarkers (IL1b, ferritin) & 5-6% loss of SC fat https://t.co/iJOgZ5kHLb
PSS.hands_.Raynauds.jpg (keep)

Cancer Risk with Scleroderma

Sep 22, 2022

Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.

The registry included 1930 patients with SSc and were compared to a matched general population to derive the

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
RheumNow Podcast square

CD19 CAR T Cell Therapy in SLE (9.16.2022)

Sep 16, 2022

The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review

Read Article
colitis.jpg

IBD Ups Risk of Psoriatic Disease

Sep 15, 2022

Findings of a new study suggest a causal effect between inflammatory bowel disease (IBD) and psoriasis (PSO) as well as psoriatic arthritis (PsA), but not vice versa.



A mendelian randomization study based on genome-wide association studies including up to 463 372 European individuals

Read Article
cancer.melanoma.jpg

Does Methotrexate Use Lead to Melanoma?

Sep 15, 2022

A systematic review suggests that low-dose methotrexate (MTX) use is associated with an increased melanoma risk, but the absolute risk increase could be considered negligible.

Read Article
FDA,approved,stamp,blue

First In Class, TYK2 Inhibitor FDA Approved for Psoriasis

Sep 12, 2022

Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.

Read Article
FDA has approvef deucravacitinib (Sotyktu), an oral TYK2 inhibitor, for use in adults with Moderate-to-Severe Plaque Psoriasis. Approval was based on pivotal Phase 3 POETYK PSO clinical trials demonstrated superior efficacy over PBO & apremilast https://t.co/mkRgVZ0Crh https://t.co/833jGV1yO4
FDA has approved SPEVIGO® (spesolimab-sbzo) an IV injection - the first-approved treatment option for generalized pustular psoriasis (GPP) FLARES. Spesolimab is an interleukin-36 receptor antagonist. https://t.co/zmuB1tyw9W https://t.co/bJiQB5qJNl
myositis, polymyositis, wikipedia

EULAR/ACR Classification in MDA5+ Myositis Patients

The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM is less

Read Article
Bullous,SLE

Bullous Systemic Lupus Erythematosus

Aug 24, 2022

Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).



As goes SLE, bullous disease typically affects women, especially those of African descent.

Read Article
SI AS SpA ACR

Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis

Aug 22, 2022

A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis.



Researchers examined two PsA and AS cohorts -  patients with PsA with axial disease and isolated axial patients with AS with

Read Article
RheumNow Podcast square

Managing JDM with Calcinosis

Aug 19, 2022

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.




  1. CDC report of fungal infx in US 2019 - coccidioidomycosis (20,061), histoplasmosis (1,124) & blastomycosis (240

Read Article
PSS.scleroderma.arthritis.contractures

Rituximab Efficacy in Systemic Sclerosis

Aug 18, 2022

The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.

Read Article
SCLE,DIL,PPI

Drug-Induced Lupus from Proton Pump Inhibitors

Aug 17, 2022

A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.



This was surmised from a study of Vigibase, a WHO funded pharmacovigilance database, that

Read Article
Sleep.fatigue.doctor.jpg

Fatigue is Under-Appreciated in Psoriatic Arthritis

Aug 09, 2022

Patient-reported fatigue is high in patients with psoriatic arthritis (PsA) and often goes under-recognized by physicians. Fatigue importantly impacts physical functioning, work productivity, and health related quality of life (HRQoL).

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Aug 05, 2022

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.




  1. 521 clinically suspect arthralgia (CSA) pts were

Read Article
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc
Here's a reference for the Salmon-pink skin rashes in adult-onset Still's disease; distinctive in color (faint, salmon-pink), distribution (trunk, neck extremities), and evanescence (comes and goes within the same day). These are not static eruptions! https://t.co/BgzyQeiLyW https://t.co/c3aolVfpav
infusion.biologic.jpg

ICYMI: Drug Survival Differences in RA, PsA, SpA and PsO

Jul 07, 2022

Drug survival may be the best measure of efficacy and safety. A study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an

Read Article
RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
Danish IBD+RA registry study of TNFi induced Psoriasis in 109k non-PSO pts (20K on TNFi). PSO risk equal betw non-TNFi & conventional Rx. Compared to latter, TNFi increased nonpustular PSO (HR 2.12; NNH 342 PY) & pustular PSO (HR 6.5; NNH 909 PY) https://t.co/5l3qlyYoFy https://t.co/Ce4RmnfHOm
GRAPPA,PsA,guideline

New Updated GRAPPA Psoriatic Arthritis Recommendations

Jun 29, 2022

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,

Read Article
×